Substance P-saporin for the treatment of intractable pain

Hugh Nymeyer, Douglas A. Lappi, Denise Higgins, Carl E. Noe, Arthur E. Frankel

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Pain is a worldwide chronic health issue, and additional therapies are needed for the management of severe pain. Substance P-Saporin (SP-SAP) covalently links a biological toxin (SAP) and an endogenous peptide (SP) that targets that toxin to the subset of neurons expressing the NK1 receptor. SP-SAP, currently in phase I clinical trials, is unique as the only targeted toxin for pain to undergo human testing.We review the history of SP-SAP and related NK1-receptor targeted toxins. We review animal data on the safety and efficacy of SP-SAP for the treatment of pain in light of the results of NK1 receptor antagonists and knockouts/knockdowns of either SP or the NK1 receptor. Finally, we discuss possible mechanisms of action of SP-SAP.

Original languageEnglish (US)
Title of host publicationMilestones in Drug Therapy
PublisherSpringer Basel
Pages107-130
Number of pages24
DOIs
StatePublished - 2017

Publication series

NameMilestones in Drug Therapy
ISSN (Print)22966056

Fingerprint

Intractable Pain
Immunotoxins
Pain
Biological Toxins
Therapeutics
Clinical Trials, Phase I
Pain Management
History
substance P-saporin
Safety
Neurons
Peptides

Keywords

  • Allodynia
  • Hyperalgesia
  • NK1
  • Pain
  • SP-SAP
  • Substance P

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Nymeyer, H., Lappi, D. A., Higgins, D., Noe, C. E., & Frankel, A. E. (2017). Substance P-saporin for the treatment of intractable pain. In Milestones in Drug Therapy (pp. 107-130). (Milestones in Drug Therapy). Springer Basel. https://doi.org/10.1007/978-3-319-46877-8_6

Substance P-saporin for the treatment of intractable pain. / Nymeyer, Hugh; Lappi, Douglas A.; Higgins, Denise; Noe, Carl E.; Frankel, Arthur E.

Milestones in Drug Therapy. Springer Basel, 2017. p. 107-130 (Milestones in Drug Therapy).

Research output: Chapter in Book/Report/Conference proceedingChapter

Nymeyer, H, Lappi, DA, Higgins, D, Noe, CE & Frankel, AE 2017, Substance P-saporin for the treatment of intractable pain. in Milestones in Drug Therapy. Milestones in Drug Therapy, Springer Basel, pp. 107-130. https://doi.org/10.1007/978-3-319-46877-8_6
Nymeyer H, Lappi DA, Higgins D, Noe CE, Frankel AE. Substance P-saporin for the treatment of intractable pain. In Milestones in Drug Therapy. Springer Basel. 2017. p. 107-130. (Milestones in Drug Therapy). https://doi.org/10.1007/978-3-319-46877-8_6
Nymeyer, Hugh ; Lappi, Douglas A. ; Higgins, Denise ; Noe, Carl E. ; Frankel, Arthur E. / Substance P-saporin for the treatment of intractable pain. Milestones in Drug Therapy. Springer Basel, 2017. pp. 107-130 (Milestones in Drug Therapy).
@inbook{3422d7a989ce4b6ab85cb9fa1f1d4370,
title = "Substance P-saporin for the treatment of intractable pain",
abstract = "Pain is a worldwide chronic health issue, and additional therapies are needed for the management of severe pain. Substance P-Saporin (SP-SAP) covalently links a biological toxin (SAP) and an endogenous peptide (SP) that targets that toxin to the subset of neurons expressing the NK1 receptor. SP-SAP, currently in phase I clinical trials, is unique as the only targeted toxin for pain to undergo human testing.We review the history of SP-SAP and related NK1-receptor targeted toxins. We review animal data on the safety and efficacy of SP-SAP for the treatment of pain in light of the results of NK1 receptor antagonists and knockouts/knockdowns of either SP or the NK1 receptor. Finally, we discuss possible mechanisms of action of SP-SAP.",
keywords = "Allodynia, Hyperalgesia, NK1, Pain, SP-SAP, Substance P",
author = "Hugh Nymeyer and Lappi, {Douglas A.} and Denise Higgins and Noe, {Carl E.} and Frankel, {Arthur E.}",
year = "2017",
doi = "10.1007/978-3-319-46877-8_6",
language = "English (US)",
series = "Milestones in Drug Therapy",
publisher = "Springer Basel",
pages = "107--130",
booktitle = "Milestones in Drug Therapy",

}

TY - CHAP

T1 - Substance P-saporin for the treatment of intractable pain

AU - Nymeyer, Hugh

AU - Lappi, Douglas A.

AU - Higgins, Denise

AU - Noe, Carl E.

AU - Frankel, Arthur E.

PY - 2017

Y1 - 2017

N2 - Pain is a worldwide chronic health issue, and additional therapies are needed for the management of severe pain. Substance P-Saporin (SP-SAP) covalently links a biological toxin (SAP) and an endogenous peptide (SP) that targets that toxin to the subset of neurons expressing the NK1 receptor. SP-SAP, currently in phase I clinical trials, is unique as the only targeted toxin for pain to undergo human testing.We review the history of SP-SAP and related NK1-receptor targeted toxins. We review animal data on the safety and efficacy of SP-SAP for the treatment of pain in light of the results of NK1 receptor antagonists and knockouts/knockdowns of either SP or the NK1 receptor. Finally, we discuss possible mechanisms of action of SP-SAP.

AB - Pain is a worldwide chronic health issue, and additional therapies are needed for the management of severe pain. Substance P-Saporin (SP-SAP) covalently links a biological toxin (SAP) and an endogenous peptide (SP) that targets that toxin to the subset of neurons expressing the NK1 receptor. SP-SAP, currently in phase I clinical trials, is unique as the only targeted toxin for pain to undergo human testing.We review the history of SP-SAP and related NK1-receptor targeted toxins. We review animal data on the safety and efficacy of SP-SAP for the treatment of pain in light of the results of NK1 receptor antagonists and knockouts/knockdowns of either SP or the NK1 receptor. Finally, we discuss possible mechanisms of action of SP-SAP.

KW - Allodynia

KW - Hyperalgesia

KW - NK1

KW - Pain

KW - SP-SAP

KW - Substance P

UR - http://www.scopus.com/inward/record.url?scp=85017300709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017300709&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-46877-8_6

DO - 10.1007/978-3-319-46877-8_6

M3 - Chapter

AN - SCOPUS:85017300709

T3 - Milestones in Drug Therapy

SP - 107

EP - 130

BT - Milestones in Drug Therapy

PB - Springer Basel

ER -